MiMedx Group (NASDAQ:MDXG) Releases Earnings Results

MiMedx Group (NASDAQ:MDXG) released its quarterly earnings results on Wednesday. The company reported ($0.01) earnings per share for the quarter, FiscalAI reports. The business had revenue of $62.28 million for the quarter, compared to analysts’ expectations of $68.56 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.

Here are the key takeaways from MiMedx Group’s conference call:

• Surgical revenue grew 9% year over year, with volume increasing in the mid-teens and broad-based growth across placental sheets, particulates, and newer products. Management expects high-single-digit surgical growth in the fourth quarter.
• Total third-quarter sales fell 45% to $62 million, driven by a 71% decline in wound-care revenue following Medicare reimbursement changes. Although wound-care-center volume rose 7% sequentially, management said the market remains difficult to forecast and expects 2027 conditions to resemble 2026.
• Cost reductions and manufacturing improvements helped gross margin improve to 80% and returned the company to positive Adjusted EBITDA of $2 million, a roughly $10 million sequential improvement. Management expects further sequential EBITDA improvement in the fourth quarter and ended the period with $121 million in net cash and no debt.
• MiMedx reached a $25 million patent settlement and licensing agreement, while a federal court vacated the FDA’s adverse classification of AXIOFILL and remanded the matter for further consideration. Two additional patent cases remain active, with management citing favorable claim-construction rulings.
• The FTC issued a second request for information regarding the Sanara MedTech acquisition, delaying the closing timeline and triggering a ticking fee on MiMedx’s proposed $300 million acquisition financing. Management remains committed to the transaction, which it expects would add more than $100 million of revenue, at least $20 million in annual synergies, and an Adjusted EBITDA margin above 20%, but no closing date was provided.

MiMedx Group Price Performance

MiMedx Group stock traded up $0.05 during midday trading on Wednesday, reaching $3.95. 1,257,161 shares of the company were exchanged, compared to its average volume of 1,296,922. The firm’s 50-day simple moving average is $4.51 and its 200-day simple moving average is $4.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.79 and a current ratio of 5.33. The company has a market capitalization of $575.75 million, a price-to-earnings ratio of 98.77 and a beta of 1.18. MiMedx Group has a 1 year low of $3.03 and a 1 year high of $7.97.

Analysts Set New Price Targets

MDXG has been the subject of several recent analyst reports. Craig Hallum boosted their target price on MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Wall Street Zen upgraded shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Cantor Fitzgerald restated an “overweight” rating on shares of MiMedx Group in a research report on Tuesday, September 15th. Seaport Research Partners cut shares of MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Finally, Weiss Ratings raised shares of MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, August 27th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.57.

About MiMedx Group

MiMedx Group, Inc (NASDAQ: MDXG) is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company’s products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx’s portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.